about
Melanoma: From Incurable Beast to a Curable Bet. The Success of ImmunotherapySorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Science gone translational: the OX40 agonist storyImmunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapiesLarge molecular systems landscape uncovers T cell trapping in human skin cancer.Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaquesA novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cellsB-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cellsSafety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasSleeping beauty system to redirect T-cell specificity for human applications.In vivo discovery of immunotherapy targets in the tumour microenvironment.Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor.Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.An initial in vitro investigation into the potential therapeutic use of SupT1 cells to prevent AIDS in HIV-seropositive individualsHuman cell-based artificial antigen-presenting cells for cancer immunotherapy.Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.Th cells promote CTL survival and memory via acquired pMHC-I and endogenous IL-2 and CD40L signaling and by modulating apoptosis-controlling pathways.CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptorGenetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.Adoptive cell therapy for patients with melanoma.Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.Treating cancer with genetically engineered T cells.Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacyIL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptorsReplication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.Alternative blood products and clinical needs in transfusion medicineInfusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.Screening and identification of human ZnT8-specific single-chain variable fragment (scFv) from type 1 diabetes phage display library.Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs.Directed differentiation of induced pluripotent stem cells towards T lymphocytes.Genetically modified T-cell therapy for osteosarcomaGene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer modelHow do CARs work?: Early insights from recent clinical studies targeting CD19.Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice.Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells.
P2860
Q26798404-D9ACE8F9-222F-46D9-AD72-67BBD76C214EQ27002575-21C06C82-5536-4C29-8CFA-2194C11C87C8Q27022436-79385E9C-F74A-4F9B-BE1E-6897BAE1C549Q27027243-3DE70D3C-D44B-4062-A319-A87DC44BFFFDQ27302197-65862B27-BBA4-49B1-BD72-D4231CAC4220Q27314843-D7F9A828-8758-4FA0-9514-D5CC10705D61Q27345360-6D61EB41-97DE-4F4D-8C73-BD040F74B0E9Q29620717-99486B8A-39EB-4119-94A2-1D5D21D70C2BQ29622949-35CC324D-169A-4A88-849C-522F8281DA4DQ30535187-A55465E2-AEA6-44AA-AE0F-61DF0D053C63Q33736396-03772BA5-ABB8-422B-93D2-7D648AC63864Q34042430-D5B27C94-3EDB-433E-BCDE-CEBF9359F78CQ34122292-C520A7A1-844C-4F0E-9086-E2363F875CF9Q34270375-3662602D-18F7-4849-B588-D35B3BF0EBF2Q34304964-9D1C523B-6834-4036-9BBB-A8BAF7C9FD65Q34391263-D75BBEC0-DF46-46F0-94A6-A8B358109B8DQ34557953-6AFED950-E40E-46F3-A930-B17FD1327C85Q34621730-E216AD0A-18E0-409B-824B-E74ADD842921Q34778623-241BB1A3-B1BF-496B-86B2-0738B14201A3Q34981606-A73EAE8B-D811-4392-9CCE-CCA6D19F9D9DQ35001971-8929784F-0D8A-44E6-89C2-4D37D2D5FA75Q35057983-23B8525E-2728-4977-A3DD-B46588A7C547Q35223241-C4CC1D45-E66A-4BB5-896E-02CA47BBF780Q35285859-04601DF9-E654-4B45-A950-945E024BA75AQ35353365-4C29BAB4-6667-41E2-9DD2-D381D583F547Q35399080-41731FB2-726A-4C56-9C2F-A72727E1C721Q35578622-7F458035-8E63-4F72-95D2-4F35489AEAFBQ35689938-40E2FA5C-6009-48B0-8C40-9701730132C4Q35749986-EF120EC0-5FCD-421D-A408-9B17A17BB42BQ35776868-6B6353CC-7D6E-47F7-B6D4-EDAE73027E0AQ35915095-5A01B6C4-E4CE-4324-8D07-9CCDE061112DQ35988657-0D1A44EB-A8CE-4A6F-AC9E-19D317DFCAD8Q36043179-968F575B-6A47-4E4B-8A1A-A042A3F77202Q36073562-BF829737-A4ED-4369-A52A-8ADFA42CAB71Q36076969-B76B2DBD-6972-47BF-81D5-F0ED2C59A8E0Q36198232-8AD0846A-7E25-4657-BE1B-90C1B14AE35AQ36345439-BBB2C3AD-D7CA-4996-AFB2-761AD8C9CDF4Q36476104-484A1F9E-917E-4437-B7C0-529BABFD9D65Q36688932-96A71D2C-DBAD-4F54-87A1-F1A9988423E6Q37389364-B5D4A8BD-46B0-4A7A-89FF-6A4E18EB1C5B
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Adoptive T cell therapy of cancer.
@ast
Adoptive T cell therapy of cancer.
@en
Adoptive T cell therapy of cancer.
@nl
type
label
Adoptive T cell therapy of cancer.
@ast
Adoptive T cell therapy of cancer.
@en
Adoptive T cell therapy of cancer.
@nl
prefLabel
Adoptive T cell therapy of cancer.
@ast
Adoptive T cell therapy of cancer.
@en
Adoptive T cell therapy of cancer.
@nl
P2860
P1476
Adoptive T cell therapy of cancer.
@en
P2093
Helen E Heslop
Malcolm K Brenner
P2860
P304
P356
10.1016/J.COI.2010.01.020
P577
2010-02-17T00:00:00Z